Seeing Is Believing
Currently out of the existing stock ratings of Serge Belanger, 410 are a BUY (92.13%), 35 are a HOLD (7.87%).
Analyst Serge Belanger, currently employed at NEEDHAM, carries an average stock price target met ratio of 27.12% that have a potential upside of 51.85% achieved within 226 days.
Serge Belanger’s has documented 864 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ARQT, Arcutis Biotherapeutics at 07-Aug-2025.
Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for KALV (KALVISTA PHARMACEUTICALS) at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
4 months 1 days ago
(10-Apr-2025)
6/6 (100%)
$3.41 (15.79%)
263
Hold
$32
$10.38 (48.01%)
$36
4 months 21 days ago
(21-Mar-2025)
10/15 (66.67%)
$3.71 (13.11%)
337
Buy
$55
$33.38 (154.39%)
$62
11 months 30 days ago
(12-Aug-2024)
2/5 (40%)
$11.75 (27.17%)
105
Buy
$117
$95.38 (441.17%)
$63
1 years 5 months 14 days ago
(28-Feb-2024)
1/2 (50%)
$62.26 (113.74%)
48
Hold
$44
$22.38 (103.52%)
$40
2 years 2 months 25 days ago
(17-May-2023)
5/5 (100%)
$1.03 (2.40%)
86
Which stock is Serge Belanger is most bullish on?
Which stock is Serge Belanger is most reserved on?
What Year was the first public recommendation made by Serge Belanger?